Information on patients with WM and HDs
| . | HD . | WM + no BTKi . | WM + BTKi . |
|---|---|---|---|
| Number | 15 | 13 | 5 |
| Age (y) | NR (18-60) | 73 (50-87) | 74 (52-91) |
| Sex | |||
| Male | NR | 8 (62%) | 2 (40%) |
| Female | NR | 5 (38%) | 3 (60%) |
| BM involvement (% cellularity) | NT | 43 (5-80) | 22 (2-70) |
| IgM (g/L) | NT | 23 (3-78) | 7 (2-11) |
| Active treatments | |||
| None | 15 (100%) | 13 (100%) | 0 (0%) |
| Ibrutinib | 0 (0%) | 3 (60%) | |
| Zanubrutinib | 0 (0%) | 2 (40%) | |
| Past treatments∗ | |||
| None | NR | 4 (33%) | 2 (40%) |
| R-CVP | 6 (50%) | 1 (20%) | |
| BR | 3 (25%) | 1 (20%) | |
| DRC | 2 (17%) | 0 (0%) | |
| Ibrutinib | 1 (8%) | 1 (20%) | |
| Rituximab | 2 (17%) | 0 (0%) | |
| R-FC | 1 (17%) | 0 (0%) | |
| CR | 1 (8%) | 0 (0%) | |
| Chlorambucil | 1 (8%) | 0 (0%) | |
| CP | 1 (8%) | 0 (0%) | |
| Comorbidities | |||
| None | NT | 2 (17%) | 1 (20%) |
| Cardiovascular | 4 (33%) | 2 (40%) | |
| Hypertension | 2 (17%) | 2 (40%) | |
| Atrial fibrillation | 2 (17%) | 0 (0%) | |
| Ischemic heart disease + stent | 1 (8%) | 1 (20%) | |
| Dyslipidemia | 1 (8%) | 0 (0%) | |
| Cerebral vascular accident | 1 (8%) | 0 (0%) | |
| Aortic stenosis | 1 (8%) | 0 (0%) | |
| Dilated cardiomyopathy | 1 (8%) | 0 (0%) | |
| Patent ductus arteriosus | |||
| Infection/inflammation | 3 (25%) | 0 (0%) | |
| Arthritis | 3 (25%) | 0 (0%) | |
| Recurrent infections | 2 (17%) | 0 (0%) | |
| Sepsis | 1 (8%) | 0 (0%) | |
| Asbestosis | 1 (8%) | 0 (0%) | |
| Glomerulonephritis | 1 (8%) | 0 (0%) | |
| Meningitis | 1 (8%) | 0 (0%) | |
| Sarcoidosis | 1 (8%) | 0 (0%) | |
| Chronic obstructive airway disease | |||
| Vasculitis | 1 (8%) | 0 (0%) | |
| Shingles | 0 (0%) | 1 (20%) | |
| Additional malignancy | |||
| Cryoglobulinemia | 2 (17%) | 0 (0%) | |
| Prostate cancer | 1 (8%) | 0 (0%) | |
| Thoracic mass | 1 (8%) | 0 (0%) | |
| Schwannoma of lumbar spine | 1 (8%) | 0 (0%) | |
| Lower abdomen mass | 1 (8%) | 0 (0%) | |
| Squamous cell carcinoma | 0 (0%) | 2 (40%) | |
| Myelodysplastic syndrome | 0 (0%) | 1 (20%) | |
| RBC count (×1012/L) | 4.1 (3.5-5.8) | 3.0 (1.8-4.4) | 3.4 (2.8-3.9) |
| Hemoglobin (g/L) | 132 (113-199) | 105 (749-142) | 110 (74-128) |
| WBC count (×109/L) | 5.6 (3.8-8.0) | 4.3 (2.0-6.3) | 5.6 (2.3-8.5) |
| Lymphocyte count (×109/L) | 1.9 (1.0-2.5) | 1.3 (0.3-2.1) | 0.5 (0.7-2.6) |
| Platelet count (×109/L) | 207 (73-264) | 151 (35-285) | 143 (72-202) |
| MPV (fL) | 7.4 (6.7-8.7) | 7.6 (6.7-9.4) | 8.5 (7.3-9.7) |
| . | HD . | WM + no BTKi . | WM + BTKi . |
|---|---|---|---|
| Number | 15 | 13 | 5 |
| Age (y) | NR (18-60) | 73 (50-87) | 74 (52-91) |
| Sex | |||
| Male | NR | 8 (62%) | 2 (40%) |
| Female | NR | 5 (38%) | 3 (60%) |
| BM involvement (% cellularity) | NT | 43 (5-80) | 22 (2-70) |
| IgM (g/L) | NT | 23 (3-78) | 7 (2-11) |
| Active treatments | |||
| None | 15 (100%) | 13 (100%) | 0 (0%) |
| Ibrutinib | 0 (0%) | 3 (60%) | |
| Zanubrutinib | 0 (0%) | 2 (40%) | |
| Past treatments∗ | |||
| None | NR | 4 (33%) | 2 (40%) |
| R-CVP | 6 (50%) | 1 (20%) | |
| BR | 3 (25%) | 1 (20%) | |
| DRC | 2 (17%) | 0 (0%) | |
| Ibrutinib | 1 (8%) | 1 (20%) | |
| Rituximab | 2 (17%) | 0 (0%) | |
| R-FC | 1 (17%) | 0 (0%) | |
| CR | 1 (8%) | 0 (0%) | |
| Chlorambucil | 1 (8%) | 0 (0%) | |
| CP | 1 (8%) | 0 (0%) | |
| Comorbidities | |||
| None | NT | 2 (17%) | 1 (20%) |
| Cardiovascular | 4 (33%) | 2 (40%) | |
| Hypertension | 2 (17%) | 2 (40%) | |
| Atrial fibrillation | 2 (17%) | 0 (0%) | |
| Ischemic heart disease + stent | 1 (8%) | 1 (20%) | |
| Dyslipidemia | 1 (8%) | 0 (0%) | |
| Cerebral vascular accident | 1 (8%) | 0 (0%) | |
| Aortic stenosis | 1 (8%) | 0 (0%) | |
| Dilated cardiomyopathy | 1 (8%) | 0 (0%) | |
| Patent ductus arteriosus | |||
| Infection/inflammation | 3 (25%) | 0 (0%) | |
| Arthritis | 3 (25%) | 0 (0%) | |
| Recurrent infections | 2 (17%) | 0 (0%) | |
| Sepsis | 1 (8%) | 0 (0%) | |
| Asbestosis | 1 (8%) | 0 (0%) | |
| Glomerulonephritis | 1 (8%) | 0 (0%) | |
| Meningitis | 1 (8%) | 0 (0%) | |
| Sarcoidosis | 1 (8%) | 0 (0%) | |
| Chronic obstructive airway disease | |||
| Vasculitis | 1 (8%) | 0 (0%) | |
| Shingles | 0 (0%) | 1 (20%) | |
| Additional malignancy | |||
| Cryoglobulinemia | 2 (17%) | 0 (0%) | |
| Prostate cancer | 1 (8%) | 0 (0%) | |
| Thoracic mass | 1 (8%) | 0 (0%) | |
| Schwannoma of lumbar spine | 1 (8%) | 0 (0%) | |
| Lower abdomen mass | 1 (8%) | 0 (0%) | |
| Squamous cell carcinoma | 0 (0%) | 2 (40%) | |
| Myelodysplastic syndrome | 0 (0%) | 1 (20%) | |
| RBC count (×1012/L) | 4.1 (3.5-5.8) | 3.0 (1.8-4.4) | 3.4 (2.8-3.9) |
| Hemoglobin (g/L) | 132 (113-199) | 105 (749-142) | 110 (74-128) |
| WBC count (×109/L) | 5.6 (3.8-8.0) | 4.3 (2.0-6.3) | 5.6 (2.3-8.5) |
| Lymphocyte count (×109/L) | 1.9 (1.0-2.5) | 1.3 (0.3-2.1) | 0.5 (0.7-2.6) |
| Platelet count (×109/L) | 207 (73-264) | 151 (35-285) | 143 (72-202) |
| MPV (fL) | 7.4 (6.7-8.7) | 7.6 (6.7-9.4) | 8.5 (7.3-9.7) |
Values are displayed as number (%) or mean (range). P values were determined by Mann-Whitney t test. Data for HD age, sex, and any past treatments were not collected due to ethics protocol requirements. All current HD medications were screened before blood collection. Patients may have had >1 prior treatment or comorbidity.
BR, bendamustine and rituximab; CR, chlorambucil and rituximab; CP, chlorambucil and prednisolone; DRC, dexamethasone, rituximab, and cyclophosphamide; MPV, mean platelet volume; NR, not recorded; NT, not tested; R-CVP, rituximab, cyclophosphamide, vincristine, and prednisolone; R-FC, rituximab, fludarabine, and cyclophosphamide.
Not all medications were recorded, including but not limited to historical use of anticoagulant, antiplatelet and nonsteroidal anti-inflammatory drug therapies to treat comorbidities.